MRK Jan 2025 82.500 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 01:03PM EDT. Market open.
| Previous Close | 40.95 |
| Open | 40.95 |
| Bid | 43.00 |
| Ask | 47.25 |
| Strike | 82.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 40.95 - 40.95 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 56 |
Business WireMerck to Acquire EyeBio
RAHWAY, N.J. & NEW YORK, May 29, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
ReutersMerck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck has said it's in the market for deals of up to around $15 billion as it plans ways to deal with a loss of revenue from its aging cancer immunotherapy Keytruda.
- Investing.com
Merck nears $1.3 bln takeover of Eyebiotech- WSJ
Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech, granting the pharmaceutical giant entry into the rapidly growing eyecare market, the Wall Street Journal reported on Tuesday.
© 2024 Yahoo. All rights reserved.